Product Highlights

• Technetium-99m-labeled drug for myocardial perfusion imaging for detection of coronary artery disease¹
• Indicated for use with approved pharmacologic stress agents for known or suspected CAD¹
• High target-to-background ratio provides clearer images^1,2,3
• Improved image clarity provides confident diagnosis^2,4
• Demonstrates good sensitivity, specificity, and diagnostic accuracy⁴
• Earlier imaging and higher quality images possible from 15 minutes to 4 hours postinjection^1-3

Product Description

A cardiac imaging agent that is labeled with technetium 99m, MYOVIEW is useful in the diagnosis and localization of regions of reversible myocardial ischemia in the presence or absence of infarction under exercise and rest conditions. Imaging can begin as soon as 15 minutes or up to 4 hours after administration of MYOVIEW, enhancing patient management and department flexibility. The product was approved by the FDA in February 1996.

References: 1. MYOVIEW Prescribing Information. 2. Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino] ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993;34:30-38. 3. Munch G, Neverve J, Matsunari I, Schroter G, Schwaiger M. Myocardial technetium-99m-tetro- fosimin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease. J Nuc/ Med. 1997;38:428-432. 4. Jain D. Technetium-99m labeled myocardial perfusion imaging agents. Semin Nucl Med. July 1999:29:221-236.

In studying patients with known or suspected coronary artery disease, care should be taken to ensure continuous cardiac monitoring and the availability of emergency cardiac treatment. As with all injectable drug products, allergic reactions, and anaphylaxis may occur. Pharmacologic induction of cardiovascular stress may be associated with serious adverse events, such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent's labeling. The most common adverse reactions reported from post-marketing experience included rash, urticaria, abnormal vision, allergic reactions, and fever.